BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Biosig cleared to test merimepodib plus remdesivir in COVID-19US biotech BioSig Technologies’ subsidiary ViralClear has been cleared by the FDA to start a phase 2 trial Share XBiosig cleared to test merimepodib plus remdesivir in COVID-19https://pharmaphorum.com/news/biosig-cleared-to-test-merimepodib-plus-remdesivir-in-covid-19/
